

OMB No.: 0925-0642
Expiration Date: 5/31/2020

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-XXXX). Do not return the completed form to this address.

General Questions

Please select the best response for each question.

1. What is your role in NCORP? (Check all that apply)

- PI or Investigator
- Clinical / Research Staff
- NCORP Administrator
- NCI Staff
- CCDR Lead
- Other (please specify)

2. What type of NCORP grantee do you represent?

- Community Site
- Research Base
- Minority/Underserved Community Site
- Not Applicable
-



2017 NCORP Annual Meeting

Day 1 - Monday August 28 2017

For each session, please select the response which best represents the extent to which you agree or disagree with the statements below.

3. The following sessions (titles and presenters below) provided useful information for my NCORP role.

	Agree	Neutral	Disagree
NCORP Year in Review (Worta McCaskill-Stevens, MD, MS)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Keynote: Cancer Control in the 21st Century (Otis Brawley, M.D.)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Science of CCDR (Ann Geiger, Ph.D., M.P.H.)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Communicating Costs in Oncology: Advocacy Perspective (Shelly Fuld Nasso)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Communicating Costs in Oncology: Research Perspective (Ya-Chen Tina Shih, Ph.D.)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
TMIST: Clearing the Fog (Jeannine Brant, Ph.D.)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
NCI Legislative Update: Congressional Budget Process and Resulting NIH Funding	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
NCORP Research Bases Town Hall	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

4. Was the breakout session you attended informative and relevant to your NCORP role?

	Agree	Neutral	Disagree	N/A: DID NOT ATTEND
Financial Toxicity and Cancer Care Costs: Are You Ready to Talk About It?	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Insurance and Clinical Trials	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Minority Health Disparities: Diversity Considerations	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Registration Credentialing Repository (RCR)/Delegation of Task Log (DTL) Update	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Navigating the CIRB Protocol Review Process: Tips for Success	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

5. Was the breakout session useful and relevant to your NCORP role?

- Agree
- Neutral
- Disagree

6. Any additional comments/feedback on the day 1 plenary or breakout sessions?

For each session, please select the response which best represents the extent to which you agree or disagree with the statements below.

7. The following sessions (titles and presenters below) provided useful information for my NCORP role.

	Agree	Neutral	Disagree
radiation Therapy Quality Assurance in Clinical Trials: Why and How (Dave Followill, Ph.D.)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
CTEP Update (Meg Mooney, M.D.)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
CIRB Update: Spotighting Local Issues (Laura Covington)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Considerations and Process for Applying for an NCI RFA (Michael Small, Ph.D.)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Grants Administration (Sean Hine)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

8. Was the breakout session you attended informative and relevant to your NCORP role?

	Agree	Neutral	Disagree	N/A: DID NOT ATTEND
New and Upcoming NCORP CCDR Studies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Overcoming Accrual Challenges: It Can be Done!	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Clinical Trials and Elderly Accrual: Has There Been Any Progress?	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social Media for NCORP: Promotion and Recruitment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

9. Any additional comments/feedback on the day 2 plenary or breakout sessions?



2017 NCORP Annual Meeting

Overall Meeting

Please select the response which best represents the extent to which you agree or disagree with the statements below.

10. There was sufficient time to interact with my colleagues.

Agree Neutral Disagree

11. There was sufficient time to interact with NCI staff.

Agree Neutral Disagree

12. There was sufficient time for audience questions and dialogue on session topics.

Agree Neutral Disagree

13. Was the length of the NCORP Investigator Meeting?

Too long

Too short

Just right

14. Overall, how would you rate this meeting?

- Excellent
- Good
- Fair
- Poor

15. What session(s) did you find most useful and relevant?

16. What improvements or changes would you recommend for future NCORP Annual meetings?

17. What other topics would you like to see covered in future NCORP Annual meetings or NCORP webinars?